Pfizer Inc ((PFE)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pfizer Inc. and BioNTech SE are conducting a clinical study titled ‘A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS.’ The study aims to assess the safety and immune response of a modified RNA vaccine for shingles in healthy adults aged 50 to 85. This research is significant as it explores a new potential vaccine option for shingles, a condition that affects many older adults.
The intervention being tested is the Varicella Zoster Virus modRNA (VZV modRNA) vaccine. This biological treatment is designed to be administered via intramuscular injection and is compared against the existing shingles vaccine, Shingrix, to evaluate its effectiveness and safety.
The study design is interventional, with a randomized allocation and a sequential intervention model. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment assignments. The primary purpose of the study is prevention.
The study began on January 25, 2023, and is currently active but not recruiting. The primary completion and estimated completion dates are set for June 24, 2025, which is also the date of the last update. These timelines are crucial for tracking the progress and eventual results of the study.
This clinical study update could have significant market implications for Pfizer and BioNTech. A successful outcome may boost investor confidence and positively impact stock performance, especially as the companies continue to innovate in the vaccine space. Competitors in the vaccine industry will likely monitor these developments closely, as a new shingles vaccine could alter market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.